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Abstract
Objectives—Regular and quality CD4 testing is essential to monitor disease progression in 
people living with HIV. In Haiti, most laboratories have limited infrastructure and financial 
resources and have relied on manual laboratory techniques. We report the successful 
implementation of a national specimen referral network to rapidly increase patient coverage with 
quality CD4 testing while at the same time building infrastructure for referral of additional sample 
types over time.
Method—Following a thorough baseline analysis of facilities, expected workload, patient 
volumes, cost of technology and infrastructure constraints at health institutions providing care to 
HIV patients, the Haitian National Public Health Laboratory designed and implemented a national 
specimen referral network. The specimen referral network was scaled up in a step-wise manner 
from July 2011 to July 2014.
Results—Fourteen hubs serving a total of 67 healthcare facilities have been launched; in 
addition, 10 healthcare facilities operate FACSCount machines, 21 laboratories operate PIMA 
machines, and 11 healthcare facilities are still using manual CD4 tests. The number of health 
institutions able to access automated CD4 testing has increased from 27 to 113 (315%). Testing 
volume increased 76% on average. The number of patients enrolled on ART at the first healthcare 
facilities to join the network increased 182% within 6 months following linkage to the network. 
Performance on external quality assessment was acceptable at all 14 hubs.
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Conclusion—A specimen referral network has enabled rapid uptake of quality CD4 testing, and 
served as a backbone to allow for other future tests to be scaled-up in a similar way.
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Specimen referral network; CD4 testing; Hubs; Spokes; External quality assessment
Introduction
Unprecedented efforts and investment have led to drastic scale up of care and treatment for 
people living with HIV/AIDS in resource-limited countries (RLC) over the last decade. In 
2013, the Joint United Nations Program on HIV/AIDS (UNAIDS) reported More than 9.7 
million people as of 2013, in low- and middle-income countries are receiving lifelong 
antiretroviral therapy (ART) resulting in significant decline in morbidity and mortality [1]. 
Haiti is affected by the most pervasive HIV epidemic outside of sub-Saharan Africa, but a 
range of prevention and treatment efforts have been implemented, and the HIV prevalence 
in the general population has been stable over the past five years [2]. As of late 2013, more 
than 50,000 HIV-infected persons in Haiti were receiving ART, meeting more than 70% of 
the estimated need based on most recent national guidelines [1] The World Health 
Organization (WHO) guidelines recommend a minimum package of laboratory tests for 
patients with HIV that includes CD4 cell count testing [3]. Access to measurements of CD4 
cell counts is vital for determining the level of immune suppression and predicting host 
susceptibility to specific opportunistic infections [4–6]. Where resources are insufficient to 
ensure universal treatment access, the results of CD4 testing are also used to prioritize 
patients for treatment, thus CD4 testing is a gateway to early ART, which in turn reduces 
morbidity and mortality, decreases mother-to-child transmission of HIV and decreases the 
incidence of HIV-associated tuberculosis (TB) [7,8]. CD4 counts are also used as a tool to 
monitor disease progression and the effectiveness of ART, particularly in Haiti and other 
countries where viral load testing is not widely available [9]. However, there are important 
challenges limiting widespread access to CD4 cell count testing, including inconsistent 
supplies of electricity and water, poor physical infrastructures, shortage of skilled 
technicians, an inconsistent supply-chain for consumables and reagents, and inadequate 
equipment maintenance.
The need to increase availability of CD4 testing in RLC has driven the development of an 
array of cost-efficient and technically simple CD4 cell count testing platforms [4]. Two 
possible approaches to expansion of access to CD4 tests in RLC include establishment of 
decentralized testing using these platforms and development of testing networks that support 
transport of samples from peripheral healthcare facilities to centralized testing laboratories 
[10].
During initial expansion of HIV care and treatment services in Haiti, most laboratories relied 
on a manual method of CD4 testing based on microscopic evaluation of beads coated with 
antibodies directed against the CD4 and CD8 receptors on T lymphocytes (cytosphere assay; 
Coulter Corporation, Hialeah, Fla.). While the manual CD4 requires minimal equipment 
beyond a low-cost microscope and can be performed at remote health care facilities, the 
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method has low throughput (approximately 10 samples per day), is labor intensive and the 
quality of the result is hard to ensure due to the subjectivity introduced when cells are 
counted visually [11]. By 2010, only 12% of the CD4 testing needs in Haiti were being met 
with automated equipment and very few laboratories had infrastructure that would support 
automation of laboratory testing.
Many of the general challenges to expanding access to CD4 testing in RLC are specifically 
relevant in Haiti. Most laboratories in the country depend on the national electric grid which 
is not constant. In Haiti, blackouts and brownouts are common, the national utility provider 
is not able to meet the national demand for electricity, road conditions are poor and some 
facilities can only be reached by motorcycle. However, Haiti has a well-functioning, 
centralized system for drugs and laboratory commodities management for HIV care and 
treatment programs and a national public health laboratory (French acronym: LNSP) with 
good capacity for testing and expanding capacity related to implementation of national level 
laboratory programs.
In 2011, in order to expand access to quality CD4 cell count testing, Haiti established a 
specimen referral network (SRN) based mainly on a model of established central testing 
“hubs” serving more peripheral “spoke” laboratories/healthcare facilities. Needs not met 
through specimen referral were addressed using automated point-of-care testing equipment. 
While the SRN is meant to support transport of multiple types of laboratory samples over 
time, the primary initial objective was to support 80% of CD4 testing needs in the country. 
We describe of the establishment of the CD4 testing system and progress in expanding 
access to CD4 testing in Haiti.
Methods
Establishment of the CD4 cell count testing network
The first step in the establishment of the network was to create a logistics and coordination 
unit (LCU) at LNSP in early 2011. This unit was responsible for selecting the participating 
laboratories based on infrastructure, human resources, and location; for the unit was also 
charged with training laboratory technicians and specimen transporters, and for monitoring 
daily activity of the network.
In the 2nd quarter of 2011, the LCU, in collaboration with staff from the Clinton Health 
Access Initiative (CHAI) and American Public Health Laboratory (APHL), conducted an 
assessment of 20 laboratories to determine their potential to serve as testing hubs. A team 
assessed infrastructure, human resources, and laboratory capacity using the WHO/African 
Regional (AFRO) Laboratory Quality Improvement Process Towards Accreditation 
(SLIPTA) check list [12]. Following this assessment, 14 laboratories were chosen (Figure 1) 
as testing hubs based on whether they had or could reasonably be upgraded to have adequate 
space, constant electricity, running water, functioning air conditioning, available cold chain 
storage, and trained technicians. Once hub laboratories had been identified, referrals, or 
“spoke” facilities, were chosen with a travel time of less than 60 minutes from the 
corresponding hub. This generated 14 “circuits”, each composed of a hub laboratory with 
automated CD4 testing capacity (a laboratory with a FACSCount machine) and 4–8 spokes. 
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Laboratories that could not be reasonably linked to hub laboratories because of transport 
challenges were chosen to receive point of care equipment in an effort to allow the broadest 
possible access to CD4 cell count testing.
The next step was to ensure that identified hub laboratories had adequate infrastructure to 
support automated CD4 cell count testing. Electrical systems at hub laboratories were 
upgraded as needed with installation of back-up power sources, surge protection equipment, 
and inverters designed to safely power down equipment during interruptions in the main 
power supply. Air conditioning was installed at 4 hubs. Anticipated workloads were 
estimated based on the patient volume from the spoke laboratories and the pre-network 
testing volume at hub healthcare facilities; additional technicians were recruited in line with 
these estimates.
Twenty-four FACSCount (Becton Dickinson, San Jose, CA) machines and 21 PIMA (Alere 
Inc. Waltham, MA.) machines were installed. To ensure maximum performance of the 
equipment, service contracts were established with in-country representatives of Alere and 
BD Dickenson for preventive maintenance and repair of all FACSCount and PIMA in the 
network. Initial supplies needs were quantified based on anticipated testing volumes. 
Twenty five laboratory technicians were trained on automated CD4 testing using 
FACSCount and 21 laboratories received onsite training for the use of the PIMA point-of-
care machines. Twenty-eight drivers were trained in safe specimen packing and handling 
practices, transport and decontamination procedures in case of spillage. Healthcare facilities 
were provided with packaging materials for sample transport. Detailed standard operating 
procedures (SOPs) for specimen shipping, reception, rejection and for incident reports were 
developed.
Accurate CD4 T-cell enumeration is pivotal for correct clinical management of HIV/AIDS 
patients. An external quality assurance (EQA) program is critical to ensure that patients are 
accurately monitored on therapy, irrespective of methodology or geographic location [13]. 
To assess the quality of laboratory performing CD4 test, all hub laboratories were enrolled 
in Haiti’s EQA program (biannual testing of standard panels provided by Quality 
Assessment and Standardization for Immunological measures relevant to HIV (QASI) [14] 
as they were linked to the SRN. Laboratories with point-of-care CD4 were also enrolled in 
Haiti EQA program.
The SRN was piloted in July 2011 with LNSP as a testing hub and 4 nearby laboratories 
delivering specimens daily for testing at LNSP and expanded nationally.
Evaluation of the impact of network establishment
Information about the networked healthcare facilities and other routine monitoring data were 
analyzed to evaluate the impact of the SRN. Changes in national access to CD4 testing were 
analyzed for the period from December 2008 to August 2013. Testing volumes were 
analyzed for 10 circuits that had 6 months of follow up data by the time of the evaluation; 
data on testing volume 6 months prior to and 6 months after establishment of these circuits 
were analyzed. Information about the number of patients with 2 CD4 tests a year and the 
numbers of patients enrolled on ART was extracted from national program reports for 9 
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healthcare facilities that had a full year of post-network data on CD4 testing at the time of 
the evaluation. The impact of CD4 testing automation on the quality of laboratory results 
was assessed based on analysis of results of EQA evaluations; trimmed mean and standard 
deviations for all participating health care facilities around the world were provided by 
QASI for low and normal proficiency tests and Levy-Jennings charts were generated to 
evaluate the performance of all 14 hubs for the last QASI session in 2013. Data were 
analyzed using SPSS (SPSS, v13.0 Chicago: SPSS Inc.) and ArcGIS (Esri, Redlands, CA), p 
values of < .05 (Student t test) were considered significant.
Results
Three years after the launch of the pilot, all 14 planed circuits were operational, serving a 
total of 67 healthcare facilities. These circuits are shown in Figure 1. A total of 24 
laboratories have FACSCount CD4 equipment [14] hubs and 10 additional standalone 
FACSCount), 21 laboratories are operating PIMA machines and 11 are still using manual 
CD4 tests. Of 123 healthcare facilities providing care and treatment for HIV infected 
patients in Haiti, 112 (91%) have access to automated CD4 testing as of December 2013 (14 
hubs, 67 spokes, 10 labs with standalone FACSCount and 21 one labs with PIMA). Access 
to automated CD4 testing was 31% (14 of 45 facilities) in December 2008, 30% (14 of 46) 
in December 2009, 29% (15 of 51) in December 2010, 40% (27 of 61) in December 2011, 
and 52% (44 of 84) in December 2012 (Figure 2). The 112 healthcare facilities covered by 
automated CD4 testing provide care to approximately 99% (55606/56205) of the total of 
HIV infected patients enrolled and receiving ART in Haiti.
A significant increase (76%, p=0.007, Student t test) in the total volume of CD4 tests was 
observed comparing data 6 months before (6972 CD4 tests from 68 peripheral health care 
facilities) and 6 months after (12296 CD4 tests) healthcare facilities joined the SRN. Testing 
volumes for the first ten established circuits are shown in Figure 3; for two circuits, no 
testing was conducted prior establishment of the network. At the remaining healthcare 
facilities, the increase in CD4 total testing volume ranged between and 35% (circuit 4) and 
239% (circuit 3).
The percentage of patients with 2 CD4 tests per year at the first 9 healthcare centers (spokes) 
enrolled in the SRN is shown in Table 1. For 8 of the 9 healthcare centers, the absolute 
change in percentages was a median of 21%. Only one facility had a drop in coverage. The 
overall median change was +19% (Table 1). The number of patients enrolled on ART during 
the same time period increased from 8,318 to 23, 446 (182% increase).
All 14 testing hubs have been enrolled in the biannual EQA program. Analysis of results 
from the CD4 EQA program from QASI database showed that values for low and normal 
CD4 proficiency test fall within the recommended ± 2 SD from the mean for all health care 
facilities (Figure 4).
Discussion
We report the successful implementation of a national specimen referral network with 
decentralized access to laboratory testing as suggested by Nkengsong [15]. We observed 
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rapid expansion in CD4 testing with the establishment of the SRN in Haiti, from 40% of 
ART sites in 2010 having access to automated CD4 testing, to 91% in 2013. We further 
observed a marked increase in the number of new patients enrolled for ART care and 
treatment one year after implementation of the network. The SRN in Haiti has not only had 
an important impact on CD4 test availability countrywide, but it has allowed stakeholders to 
focus efforts to improve laboratory infrastructure. All 14 testing hubs have benefited from 
this particular attention and there have been improvements in electrical systems, functional 
air conditioning, running water and adequate space for laboratory testing. While we are 
unable to specifically compare the accuracy of testing prior to and following the 
establishment of the network, current EQA results reflect high-quality testing.
The choice to establish an SRN offered an opportunity to standardize laboratory equipment 
across the country, streamline management of the supply chain, and increase communication 
between laboratories in the network and at the same time to ensure good quality of results by 
enrolling all the hubs in an external quality assessment program. While we have not done a 
formal cost analysis, we believe that the implementation of the SRN was a cost effective 
way to ensure access to not only CD4 cell count testing but to also serve as a backbone for 
HIV viral load testing and MDR TB surveillance; with increased transportation costs being 
offset by lower equipment, maintenance, and human resource costs than would have been 
incurred with broader distribution of equipment.
Other countries have used different strategies to decentralize access to CD4 testing. Capacity 
for CD4 testing was strengthened in 6 African countries through distribution of flow 
cytometers at 122 laboratories [6]. The use of a SRN in Haiti (as compared to distribution of 
machines to large numbers of health care facilities) may facilitate QA/QC and service and 
maintenance of equipment, supplies distribution, training and staff retention since only 14 
testing hubs support more than 90% of the national CD4 testing needs.
Several African countries are implementing SRNs. In Zambia, a SRN has been designed to 
support enrollment in care and monitoring of HIV+ pregnant women; in Nyanza, a rural 
province of Kenya, a 35% upsurge in the number of patients enrolled on ART was observed 
only 5 months after implementing a SRN; more recently Uganda reported a successful 
implementation of a specimen transport system which increased access to early infant 
diagnosis of HIV ranging from 36% to 51% [16–18].
An important advantage of the SRN is that it can be adapted for use for other types of 
testing. The SRN in Haiti has grown not only in terms of number of laboratories covered, 
but also in terms of the number of different type of tests being offered to the population. In 
July 2013, LNSP introduced HIV viral load testing for better monitoring of HIV infected 
patients; the SRN has allowed 5 high patient-volume hospitals to benefit from viral load 
testing. The SRN also offers a platform for integrated laboratory-based surveillance. There 
are plans to further link “hub” facilities to the regional and central reference laboratories, 
and further expand the types of samples transported (for example to include transport of 
sputum samples for testing for drug-resistant TB, and slides for malaria and TB slide 
rechecking for external quality assurance programs).
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The sustainability of the SRN remains a big challenge. The SRN is supported with external 
funding with little financial involvement of the Haitian ministry of health. Efforts are 
ongoing to decrease the cost associated with the SRN with more motorcycles in the circuits 
instead of cars (where possible) and more involvement of local stakeholders at the different 
healthcare facilities being served by the SRN. The Haiti model is among the first reports to 
describe the influence of an SRN on testing volumes. Our analysis is limited because as an 
observational evaluation, we cannot rule out the influence of other factors on testing 
frequency or enrolment of patients on ART. 5.
Conclusion
The SRN has enabled rapid uptake of quality CD4 testing in Haiti through a combination of 
specimen transport from lower level peripheral health care facilities to well-equipped testing 
hubs and point of care testing at health care facilities with difficult road access. The 
experience in Haiti serves as a practical example of establishing an SRN in a resource 
limited setting.
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Figure 1. 
The Haitian specimen referral network map. Location for the14 FACSCount Hubs, the 67 
spoke laboratories, the 31 healthcare facilities using PIMA or FACSCount and the 11 
facilities still using manual CD4 are indicated as shown in the legend.
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Figure 2. 
National CD4 coverage. Comparison of the number of health care facilities with CD4 testing 
capacity (manual vs automated) in Haiti from 2008 to 2013.
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Figure 3. 
Impact of the specimen referral network on CD4 testing volume. We compared the number 
of CD4 tests performed by the first 10 networks (average of 5.5 healthcare facilities per 
network) 6 months prior to and 6 months after integrating the specimen referral network.
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Figure 4. 
Levy-Jennings plot demonstrating CD4+T-lymphocytes absolute counts (two level control: 
for low (A) and normal (B) lymphocyte absolute counts) obtained from Trial 34 on October 
2013. Each plot shows the concurrent results of CD4 EQA from the QASI program for all 
14 Hubs.
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